Lawrence Richer

Lawrence Richer

Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Canadian Journal of Cardiology
Verified
Journal Article
Open access
SRSatish R. Raj
Satish R. Raj
JGJuan C. Guzman
Juan C. Guzman
PHPaula Harvey
Paula Harvey
LRLawrence Richer
Lawrence Richer
RSRonald Schondorf
Ronald Schondorf
RSRobert S. Sheldon
Robert S. Sheldon
The current definition of postural orthostatic tachycardia syndrome (POTS) dates back to a small case series of patients with a subacute illness who presented with excessive orthostatic tachycardia and orthostatic intolerance, in the absence of another recognized disease. Conventional POTS criteria require an excessive orthostatic tachycardia in the absence of substantial orthostatic hypotension, and predominant symptoms of orthostatic intolerance, worse with upright posture and better with recumbence. POTS is a heterogeneous syndrome with likely several underlying pathophysiological processes, and not a specific disease. The primary panel for this Canadian Cardiovascular Society position statement sought to provide a contemporary update of the best evidence for the evaluation and treatment of POTS. We performed a systemic review of evidence for the evaluation of treatment of POTS using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology, and developed recommendations on the basis of the Canadian Cardiovascular Society approach to position statements. One identified problem was that numerous patients who did not meet criteria for POTS would still be given that diagnoses by providers to validate the illness even though this diagnosis is incorrect. This includes patients with postural symptoms without tachycardia, orthostatic tachycardia without symptoms, and those with orthostatic tachycardia but another overt cause for excessive tachycardia. We developed a novel nomenclature ecosystem for orthostatic intolerance syndromes to increase clarity. We also provide more clarity on how to interpret the orthostatic vital signs. These concepts will need to be prospectively assessed.

1 February 2002 in Pediatric Neurology
Verified
Journal Article
Closed access
LRLawrence Richer
Lawrence Richer
MSMichael I Shevell
Michael I Shevell
BRBernard R Rosenblatt
Bernard R Rosenblatt

1 July 2001 in Pediatric Neurology
Verified
Journal Article
Closed access
LRLawrence Richer
Lawrence Richer
MSMichael I Shevell
Michael I Shevell
SMSteven P Miller
Steven P Miller

1 July 2010 in Pediatrics
Verified
Journal Article
Closed access
PDF file
LRLawrence Richer
Lawrence Richer
KLKeri Laycock
Keri Laycock
KMKelly Millar
Kelly Millar
EFEleanor Fitzpatrick
Eleanor Fitzpatrick
SKSimi Khangura
Simi Khangura
FGfor the Pediatric Emergency Research Canada Emergency Department Migraine Group
for the Pediatric Emergency Research Canada Emergency Department Migraine Group
OBJECTIVE: Children with migraine may present to an emergency department (ED) when outpatient management has failed; however, only limited research has examined migraine-abortive medications among children. METHODS: A retrospective chart review of ED presentations for migraine or headache between July 1, 2004, and June 30, 2005, in 10 Canadian pediatric EDs was conducted. A priori, evidence-based treatments were defined as any treatment that was based on high-quality evidence and an absence of opioids as first-line agents. RESULTS: A total of 2515 records were screened, and 1694 (67.4%) met inclusion criteria. The average age of patients was 12.1 years, 14.5% (95% confidence interval [CI]: 12.1%–17.2%) of patients experienced headache >15 days per month, and 62.6% (95% CI: 55.7%–68.9%) had already used migraine-abortive therapy. Significant variations in practice for all classes of migraine-abortive medications were observed. Dopamine receptor antagonists (prochlorperazine, metoclopramide, or chlorpromazine) (39% [95% CI: 28.4%–50.8%]) and orally administered analgesics (acetaminophen and ibuprofen) (24.5% [95% CI: 23.9%–46.8%]) were prescribed most commonly. Predictors for the use of evidence-based treatment included older age (odds ratio: 1.15 [95% CI: 1.07–1.24]) and a discharge diagnosis of migraine (odds ratio: 1.84 [95% CI: 1.11–3.05]). CONCLUSIONS: Children presenting to EDs for treatment often have frequent attacks and have experienced failure of outpatient, migraine-abortive efforts. Practice variations were impressive for the care of children with migraine in these Canadian EDs.

19 April 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LRLawrence Richer
Lawrence Richer
LBLori Billinghurst
Lori Billinghurst
MLMeghan A Linsdell
Meghan A Linsdell
KRKelly Russell
Kelly Russell
BVBen Vandermeer
Ben Vandermeer
LHLisa Hartling
Lisa Hartling

7 July 2014 in Trials
Verified
Journal Article
Open access
PDF file
KBKaren M Barlow
Karen M Barlow
BBBrian L Brooks
Brian L Brooks
FMFrank P MacMaster
Frank P MacMaster
AKAdam Kirton
Adam Kirton
TSTrevor Seeger
Trevor Seeger
DDDeborah Dewey
Deborah Dewey
By the age of sixteen, one in five children will sustain a mild traumatic brain injury also known as concussion. Our research found that one in seven school children with mild traumatic brain injury suffer post-concussion syndrome symptoms for three months or longer. Post-concussion syndrome is associated with significant disability in the child and his/her family and yet there are no evidence-based medical treatments available. Melatonin has several potential mechanisms of action that could be useful following mild traumatic brain injury, including neuroprotective effects. The aim of this study is to determine if treatment with melatonin improves post-concussion syndrome in youths following mild traumatic brain injury. Our hypothesis is that treatment of post-concussion syndrome following mild traumatic brain injury with 3 or 10 mg of sublingual melatonin for 28 days will result in a decrease in post-concussion syndrome symptoms compared with placebo.